Arax Advisory Partners’s Century Therapeutics IPSC Stock Holding History

Arax Advisory Partners’s Portfolio IPSC Stock Details IPSC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$243	Hold	99	–	–	﹤0.01%	5081
2026 Q1	$224	Hold	99	–	–	﹤0.01%	3521
2025 Q4	$98	Hold	99	–	–	﹤0.01%	3827
2025 Q3	$49	Buy	+99	New	+$53	﹤0.01%	3532

Other funds holding IPSC

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Arax Advisory Partners's IPSC Position: Q2 2026 in Review

Arax Advisory Partners held its Century Therapeutics (IPSC) position steady in Q2 2026 at 99 shares worth $243. The position accounts for ﹤0.01% of the portfolio, ranked #5081.

Arax Advisory Partners first reported a position in IPSC in Q3 2025 and has held it in 4 quarters since. 100 funds tracked by Wall St. Rank hold IPSC as of Q2 2026.

Arax Advisory Partners held 99 shares of Century Therapeutics worth $243 as of Q2 2026.
Arax Advisory Partners left its Century Therapeutics share count unchanged in Q2 2026.
Century Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #5081 holding.
Arax Advisory Partners first reported a position in Century Therapeutics in Q3 2025 and has held it in 4 quarters since.
100 funds tracked by Wall St. Rank held Century Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.